Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/24/2011US7947686 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors
05/24/2011US7947685 Pyrazine-2-carboxyamide derivatives
05/24/2011US7947684 anticoagulants; immunomoderators; antiinflammatory agents
05/24/2011US7947683 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors
05/24/2011US7947682 Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
05/24/2011US7947681 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
05/24/2011US7947680 Adamantyl diamide derivatives and uses of same
05/24/2011US7947679 Fungicides
05/24/2011US7947678 Heterocyclic benzodiazepine CGRP receptor antagonists
05/24/2011US7947677 Spirolactam tricyclic CGRP receptor antagonists
05/24/2011US7947676 Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
05/24/2011US7947675 Trifluoromethylbenzamide derivatives and therapeutic uses thereof
05/24/2011US7947674 Meso-substituted porphyrins
05/24/2011US7947673 Removal excess iron from blood; using a compound such as 4-(3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl)benzoic acid
05/24/2011US7947672 Water-soluble anionic bacteriochlorophyll derivatives and their uses
05/24/2011US7947671 Synthesis of naturally occuring ecteinascidins and related compounds
05/24/2011US7947670 Benzoquinone ansamycin; administered orally; dose of 15 mg/kg; achieve an area under the curve of at least 100 ng*hr/ml; cancer, neoplastic disease state, hyperproliferative disorder; mixtures of geldanamycin analogs and crystallization inhibitors dramatically improve bioavailability
05/24/2011US7947669 Agent for improving insulin resistance
05/24/2011US7947668 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
05/24/2011US7947667 Aromatization; hydrolysis; deblocking, deprotecting; oxidation; for production of fulvestrant
05/24/2011US7947666 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs
05/24/2011US7947665 LPA receptor agonists and antagonists and methods of use
05/24/2011US7947663 Inhibitors of fatty acid amide hydrolase
05/24/2011US7947662 Folates, compositions and uses thereof
05/24/2011US7947661 Compounds for the treatment of marihuana dependence, withdrawal, and usage
05/24/2011US7947659 iRNA agents targeting VEGF
05/24/2011US7947657 Method for selective inhibition of human N-myc gene in N-myc expressing tumors through antisense and antigen peptido-nucleic acids (PNA)
05/24/2011US7947656 Processes for producing cellooligosaccharide
05/24/2011US7947463 Diagnosing cancer; measure antibody inhibitor, compare to control, reduced amounts of inhibitor indicates receptivity to cancer
05/24/2011US7947462 Methods for identifying Kremen polypeptide binding partners
05/24/2011US7947452 Oligonucleotides originating from sequences coding for the surface component of PTLV envelope proteins and their uses
05/24/2011US7947449 Methods of diagnosing pre-eclampsia or eclampsia
05/24/2011US7947313 Compositions for diabetes treatment and prophylaxis
05/24/2011US7947312 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals
05/24/2011US7947311 Insect repellent concentrate formulation
05/24/2011US7947310 Method of treating stroke or brain injury patients based on the intravenous administration of magnesium cations and concurrent administration of an oxygen gas mixture
05/24/2011US7947309 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
05/24/2011US7947308 Effervescent powders for inhalation
05/24/2011US7947303 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition
05/24/2011US7947301 Medical inserts; low concentration of antiinfection agent; efficiency; covering exterior surface with minocycline and rifampicin
05/24/2011US7947299 Compositions and techniques for localized therapy
05/24/2011US7947298 Animal repellent composition and method
05/24/2011US7947297 Plastic film; microbiocides; discoloration inhibition; heat resistance at high temperature
05/24/2011US7947296 Such as 2,4,4'-trichloro-2'-hydroxydiphenyl ether (triclosan) and zinc oxide; dicoloration inhibition; weatherproofing; radiation resistance
05/24/2011US7947295 Ophthalmic compositions containing a synergistic combination of two polymers
05/24/2011US7947291 Modified surface antigen
05/24/2011US7947282 Methods of treatment using vascular occlusion in combination therapies
05/24/2011US7947278 administer effective dose of human Egfl7 polypeptide agonist; intravenous, intra-arterial, intra-pericardial, systemic, subcutaneous, intramuscular, by inhalation, topical, transdermal; tumor growth, atherosclerosis, diabetic retinopathy, age-related maculopathy, and retrolental fibroplasia
05/24/2011US7947275 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
05/24/2011US7947262 Administering fullerenes to which are attached IgE Fc or stem cell factor (SCF) peptides
05/24/2011US7947261 Moiety is positioned between a water-soluble polymer and a reactive group; water soluble polymer such as polyethylene glycol containing a urethane linkage moiety for example, and a reactive group for conjugating with biodrugs
05/24/2011US7947257 Method of intranasal administration of granisetron
05/24/2011CA2645967C Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
05/24/2011CA2633170C Butylphthalide intravenous emulsion and application thereof
05/24/2011CA2629466C Beta-secretase modulators and methods of use
05/24/2011CA2628729C Use of pyrroloquinoline compounds to kill clinically latent microorganisms
05/24/2011CA2624589C Neramexane modified release matrix tablet
05/24/2011CA2623964C Using metal aquacomplexes for preparation pure amino acid chelates for human and veterinary use
05/24/2011CA2585253C Antimicrobial 2-deoxystreptamine compounds
05/24/2011CA2574491C Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
05/24/2011CA2568445C Immediate release formulations of memantine oral dosage forms
05/24/2011CA2544648C Analgesic compounds, their synthesis and pharmaceutical compositions containing them
05/24/2011CA2537066C Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
05/24/2011CA2533196C Use of pinolenic acid and derivatives thereof for weight management
05/24/2011CA2510167C Derivatives of asimadoline with covalently bonded acids
05/24/2011CA2509023C Multilayer dosage forms containing nsaids and triptans
05/24/2011CA2508194C Use of ibudilast as a phosphodiesterase 10a inhibitor
05/24/2011CA2506159C Fat regulation
05/24/2011CA2504663C Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases
05/24/2011CA2501395C Prolonged release pharmaceutical composition
05/24/2011CA2499690C Diaryl ethers as opioid receptor antagonist
05/24/2011CA2499195C A treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
05/24/2011CA2497569C 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
05/24/2011CA2493764C Improved treatment of cancer with glutamine
05/24/2011CA2493026C Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
05/24/2011CA2491701C Fredericamycin derivatives as drugs for tumor treatment
05/24/2011CA2491313C Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
05/24/2011CA2490888C Diaminopyrimidinecarboxamide derivative
05/24/2011CA2490239C Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
05/24/2011CA2483012C Oligonucleotide compositions and their use for the modulation of immune responses
05/24/2011CA2479737C Nanoparticulate compositions of map kinase inhibitors
05/24/2011CA2477601C 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
05/24/2011CA2472821C Process for producing fused imidazole compound, and reformatsky reagent in stable form and process for producing the same
05/24/2011CA2471642C 6-fluorobicyclo[3.1.0]hexane derivatives
05/24/2011CA2468719C Prevention and treatment of androgen-deprivation induced osteoporosis
05/24/2011CA2467552C Nicotin-or isonicotin benzothiazole derivatives
05/24/2011CA2464358C Alkyl ether derivatives or their salts
05/24/2011CA2463626C Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
05/24/2011CA2453901C Substituted 4-aminocyclohexanols
05/24/2011CA2450467C Methods for modulating bladder function
05/24/2011CA2443952C Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
05/24/2011CA2441235C Aryl and biaryl compounds having mch modulatory activity
05/24/2011CA2439787C Nitrogen-based camptothecin derivatives
05/24/2011CA2421562C A method of producing analgesia using sodium channel blocking compounds such as tetrodotoxin, saxitoxin and derivatives thereof
05/24/2011CA2415403C Method for obtaining aqueous formulations of oxidation-sensitive active principles
05/24/2011CA2401604C Method of treating cancer with anti-neurotrophin agents
05/24/2011CA2397183C Method of treating cellulite using perilla oil
05/24/2011CA2393710C Caspase inhibitors and uses thereof
05/24/2011CA2385266C Novel cell cycle checkpoint genes and proteins encoded thereby
05/24/2011CA2384378C Heterocyclic compounds useful as inhibitors of tyrosine kinases